手机看黄色大片1024,亚洲v无码一区二区三区四区观看,黄真人在线观看高清无码,极品嫩模大尺度av在线播放免费观看

產品資料

MDA PCa 2b細胞

如果您對該產品感興趣的話,可以
產品名稱: MDA PCa 2b細胞
產品型號: MDA PCa 2b
產品展商: HZbscience
產品文檔: 無相關文檔

簡單介紹

MDA PCa 2b細胞應如何避免細胞污染,細胞污染的種類可分成**、酵母菌、霉菌、病毒和霉漿菌。主要的污染原因為無菌操作技術不當、操作室環境不佳、污染之血清和污染之細胞等。嚴格之無菌操作技術、清潔的環境、與品質良好之細胞來源和培養基配制是減低污染之*好方法。MDA PCa 2b細胞何時須更換培養基?視細胞生長密度而定,或遵照細胞株基本數據上之更換時間,按時更換培養基即可。


MDA PCa 2b細胞  的詳細介紹

MDA PCa 2b細胞

細胞形態: 上皮樣

是否是腫瘤細胞: 1

物種來源: 人

ATCC Number: CRL-2422?

相關**: 腺癌

年限: 63 years old *****

運輸方式: 凍存運輸

生長狀態: 貼壁生長

數量: 大量

器官來源: 前列腺

MDA PCa 2b細胞Designations: MDA PCa 2b

Depositors: NM Navone

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens deposited as human

Morphology: epithelial


Source: Organ: prostate

Disease: adenocarcinoma

Derived from metastatic site: bone

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. MDA PCa 2b細胞Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Receptors: androgen receptor, expressed

Tumorigenic: Yes

Antigen Expression: prostate specific antigen (PSA)

DNA Profile (STR): Amelogenin: X,Y

CSF1PO: 10,12

D13S317: 11,12

D16S539: 10,11

D5S818: 12,13

D7S820: 8,10

THO1: 8,9

TPOX: 8,11

vWA: 16

Age: 63 years old *****

Gender: male

Ethnicity: Black

Comments:MDA PCa 2b細胞 MDA PCa 2b was established from a bone metastasis of 63 year old Black male with androgen-independent adenocarcinoma of the prostate.

The cell line expresses prostate specific antigen (PSA) and androgen receptor, grows in vitro and in vivo, and is androgen sensitive.

Cells from this cell line produce tumors in nude mice when injected either subcutaneously or orthotopically (intraprostatic).

This cell line is suitable for studying cell growth regulation by androgens.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated F-12K Medium, Catalog No. 30-2004. To make the complete growth medium, add the following components to the base medium:

fetal bovine serum to a final concentration of 20%

25 ng/ml cholera toxin

10 ng/ml mouse Epidermal Growth Factor

0.005 mM phosphoethanolamine

100 pg/ml hydrocortisone

45 nM selenious acid

0.005 mg/ml bovine insulin

Do not filter complete medium.

Temperature: 37.0°C

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Subculturing: Protocol:

Remove and discard culture medium.

Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.

MDA PCa 2b細胞Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.

Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

To remove trypsin-EDTA solution, transfer cell suspension to centrifuge tube and spin at approximately 125 xg for 5 to10 minutes.Discard supernatant and resuspend cells in fresh growth medium. Add appropriate aliquots of cell suspension to new culture vessels.

Place culture vessels in incubators at 37?C.


Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2004

recommended serum:ATCC 30-2020

derived from same individual:ATCC CRL-2421

purified DNA:ATCC CRL-2422D

References: 40479: Navone NM, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res. 3: 2493-2500, 1997. PubMed: 9815652

滬公網安備 31011702004356號